Official Title
Covid-19 Infection Prophylaxis With Low Dose of Doxycycline and Zinc in Health Care Workers
Brief Summary

Given the urgency of having guidelines for the management of COVID-19 in the current epidemic context and the lack of specific pharmacological treatment, Military Health recommends the launch of a multicenter, randomized, double-blind, interventional clinical trial. The aim of this study is to evaluate the efficacy of a combination of two treatments, low-dose doxcycline (100 mg/day) and Zinc (15 mg/day) (dietary supplement) in the primary prevention of COVID-19 infection in health care professionals in Tunisia compared to two control groups.

Completed
COVID19

Drug: Doxycyclin

daily (100mg)

Eligibility Criteria

Inclusion Criteria:

- No self-medication with study drugs or antivirals

- Negative COVID19 diagnosis confirmed by PCR and negative Elisa antibody assay

- No signs of COVID19

- Having given consent for the study

Exclusion Criteria:

Participation in other clinical trials aimed at primary prevention of VIDOC infection19

- Liver failure

- Known allergy to the study product

- Pregnancy or breastfeeding

- Vitamin A and E treatment in progress

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 65 Years
Countries
Tunisia
Locations

Military Hospital of Tunis
Tunis, Montfleury, Tunisia

Dacima Consulting
NCT Number
MeSH Terms
COVID-19
Doxycycline